K Margolin

Summary

Affiliation: City of Hope National Medical Center
Country: USA

Publications

  1. ncbi request reprint Molecular staging in stage II and III melanoma patients
    Kim Margolin
    Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Curr Oncol Rep 7:376. 2005
  2. ncbi request reprint Inhibition of vascular endothelial growth factor in the treatment of solid tumors
    Kim Margolin
    Departments of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Curr Oncol Rep 4:20-8. 2002
  3. ncbi request reprint Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group
    K Margolin
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    J Cancer Res Clin Oncol 128:214-8. 2002
  4. ncbi request reprint Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
    Kim Margolin
    City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Clin Cancer Res 13:3312-9. 2007
  5. ncbi request reprint Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer
    Kim A Margolin
    Department of Medical Oncology, City of Hope National Medical Center, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 11:903-11. 2005
  6. ncbi request reprint Methodologic guidelines for the design of high-dose chemotherapy regimens
    K Margolin
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California USA
    Biol Blood Marrow Transplant 7:414-32. 2001
  7. ncbi request reprint Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium
    K Margolin
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA
    Invest New Drugs 19:335-40. 2001
  8. ncbi request reprint Management of advanced germ cell cancer in patients with unfavorable prognosis
    Kim Margolin
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
    J Natl Compr Canc Netw 3:77-83. 2005
  9. ncbi request reprint Mitotic rate and younger age as predictors of sentinel lymph node positivity
    Kim Margolin
    Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Curr Oncol Rep 7:375, 376. 2005
  10. ncbi request reprint Autologous and allogeneic high-dose therapy for melanoma
    K A Margolin
    City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Curr Oncol Rep 3:338-43. 2001

Detail Information

Publications58

  1. ncbi request reprint Molecular staging in stage II and III melanoma patients
    Kim Margolin
    Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Curr Oncol Rep 7:376. 2005
  2. ncbi request reprint Inhibition of vascular endothelial growth factor in the treatment of solid tumors
    Kim Margolin
    Departments of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Curr Oncol Rep 4:20-8. 2002
    ..Clinical investigations are ongoing to test the value of VEGF-based intervention alone or in combination with other anticancer agents...
  3. ncbi request reprint Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group
    K Margolin
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    J Cancer Res Clin Oncol 128:214-8. 2002
    ..To evaluate the antitumor effects and toxicities of whole brain irradiation (WBI) with temozolomide (TMZ) administered by prolonged oral dosing in patients with melanoma metastatic to the brain...
  4. ncbi request reprint Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
    Kim Margolin
    City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Clin Cancer Res 13:3312-9. 2007
    ..This phase I study was designed to determine the maximum tolerated dose (MTD) and safety of BAY 50-4798, screen for tumor response, and assess pharmacokinetics...
  5. ncbi request reprint Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer
    Kim A Margolin
    Department of Medical Oncology, City of Hope National Medical Center, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 11:903-11. 2005
    ..The Beyer prognostic system is a valuable predictor for patients undergoing aPSCT...
  6. ncbi request reprint Methodologic guidelines for the design of high-dose chemotherapy regimens
    K Margolin
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California USA
    Biol Blood Marrow Transplant 7:414-32. 2001
    ....
  7. ncbi request reprint Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium
    K Margolin
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA
    Invest New Drugs 19:335-40. 2001
    ..Due to prolonged terminal elimination. Dolastatin-10 plasma concentrations of greater than 1 nM were sustained for 24 h in all patients studied. Dolastatin-10 is unlikely to have substantial activity in the treatment of melanoma...
  8. ncbi request reprint Management of advanced germ cell cancer in patients with unfavorable prognosis
    Kim Margolin
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
    J Natl Compr Canc Netw 3:77-83. 2005
    ..Important questions that remain to be answered include the role of new agents and the use of more sophisticated techniques to understand prognostic and predictive factors in selecting therapy for GCT...
  9. ncbi request reprint Mitotic rate and younger age as predictors of sentinel lymph node positivity
    Kim Margolin
    Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Curr Oncol Rep 7:375, 376. 2005
  10. ncbi request reprint Autologous and allogeneic high-dose therapy for melanoma
    K A Margolin
    City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Curr Oncol Rep 3:338-43. 2001
    ..It is hoped that this setting will provide an improved milieu for donor-derived immunotherapeutic intervention that takes advantage of shared tumor antigens with therapeutic potential shown in a variety of tumor vaccination studies...
  11. ncbi request reprint CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium
    Kim Margolin
    Division of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    Cancer 104:1045-8. 2005
    ..CCI-779 is not immunosuppressive when administered on an intermittent schedule, and its toxicity is modest, consisting of nausea, diarrhea, hypertriglyceridemia, thrombocytopenia, asthenia, and follicular dermatitis...
  12. ncbi request reprint Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data
    K Margolin
    Department of Medical Oncology and Therapeutics Research, City of Hope National Cancer Center, Duarte, CA 91010, USA
    J Clin Oncol 19:851-6. 2001
    ..The present study was designed to assess the safety and pharmacokinetics of weekly intravenous (IV) rhuMAbVEGF with one of three standard chemotherapy regimens...
  13. ncbi request reprint Cytokine therapy in cancer
    Kim Margolin
    City of Hope National Medical Center, Division of Medical Oncology and Therapeutics Research, 1500 E Duarte Road, Duarte, CA 91001, USA
    Expert Opin Biol Ther 8:1495-505. 2008
    ..Several cytokines have therapeutic potential when delivered exogenously alone or in combinations with chemotherapy or other biological agents...
  14. ncbi request reprint Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer
    R J Morgan
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA
    Bone Marrow Transplant 28:859-63. 2001
    ..We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal...
  15. ncbi request reprint High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival
    G Somlo
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA
    J Clin Oncol 15:2882-93. 1997
    ....
  16. ncbi request reprint Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support
    K Margolin
    Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    J Clin Oncol 14:2631-7. 1996
    ..To evaluate the activity of two cycles of high-dose ifosfamide, carboplatin, and etoposide (ICE) with autologous hematopoietic progenitor cell support (aHPCS) in patients with poor-prognosis, chemotherapeutically sensitive germ cell cancer...
  17. ncbi request reprint Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies
    G Somlo
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Biol Blood Marrow Transplant 7:284-93. 2001
    ..Tandem-cycle high-dose melphalan and cisplatin with PBPCs is feasible. Preliminary data suggest significant activity in selected patients with stage IV responding breast carcinoma...
  18. pmc Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer
    A VanderWalde
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Biol Blood Marrow Transplant 18:1273-80. 2012
    ....
  19. ncbi request reprint Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma
    A Nademanee
    Division of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA
    Clin Lymphoma 1:46-54. 2000
    ..The development of a second malignancy is a serious complication of high-dose therapy, which requires close surveillance...
  20. ncbi request reprint A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome
    H C Fung
    Division of Hematology and Bone Marrow Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 9:766-71. 2003
    ..0107 and.0038, respectively). Allogeneic SCT can cure approximately one third of patients with primary refractory AML. Cytogenetic characteristics before SCT correlate with transplantation outcome and posttransplantation relapse...
  21. ncbi request reprint Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy
    R J Morgan
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E. Duarte Rd, Duarte, CA 91010, USA
    Cancer Chemother Pharmacol 47:327-32. 2001
    ..However, prochlorperazine levels consistent with those required in vitro for drug resistance reversal are attainable within the dose range having a tolerable toxicity profile...
  22. ncbi request reprint Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies
    M L Tetef
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California 91010, USA
    Clin Cancer Res 7:1569-76. 2001
    ....
  23. ncbi request reprint Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial
    R J Morgan
    Division of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA
    Int J Gynecol Cancer 17:373-8. 2007
    ..Steady-state levels of >1 microg/mL CSA (HPLC assay) are achievable in vivo. Insufficient clinical resistance reversal was observed in this study to warrant further investigation of this combination...
  24. ncbi request reprint Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed
    H C Fung
    Division of Hematology and Bone Marrow Transplantation, Kaiser Permanente City of Hope BMT Program, City of Hope Cancer Center, 1500 E Duarte Road, Duarte, CA 91010, USA
    Biol Blood Marrow Transplant 9:649-56. 2003
    ....
  25. ncbi request reprint Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma
    P Lee
    Department of Medicine, Division of Medical Oncology, Keck/University of Southern California School of Medicine, Los Angeles, USA
    J Clin Oncol 19:3836-47. 2001
    ....
  26. pmc Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer
    G Somlo
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, California, CA 91010 3000, USA
    Br J Cancer 87:281-8. 2002
    ..Validation of such models could come from recently completed randomised, prospective trials...
  27. ncbi request reprint Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors
    Thehang Luu
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Anticancer Res 30:167-74. 2010
    ..Bortezomib demonstrates synergism with gemcitabine via a fixed-dose rate (FDR). The aim of this phase I trial in solid tumors was to establish the maximum tolerated dose (MTD) and safety data for this combination...
  28. pmc Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
    Robert J Morgan
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA
    Cancer Chemother Pharmacol 66:927-33. 2010
    ....
  29. ncbi request reprint A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression
    Stephen Shibata
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
    Cancer Chemother Pharmacol 59:549-57. 2007
    ..Preclinically, gemcitabine has demonstrated synergy when combined with platinum compounds. These facts formed the rationale for determining the maximum tolerated dose (MTD) of gemcitabine in combination with oxaliplatin...
  30. ncbi request reprint Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity
    Robert J Morgan
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA
    Clin Cancer Res 13:1232-7. 2007
    ..To determine the maximally tolerated dose, toxicity, and pharmacokinetics of i.p. gemcitabine...
  31. ncbi request reprint Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium
    Kim Margolin
    Division of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010 3000, USA
    J Cancer Res Clin Oncol 133:705-11. 2007
    ..Trial endpoints were antitumor efficacy and toxicity, pharmacokinetics, and evidence of apoptosis in peripheral blood mononuclear cells...
  32. ncbi request reprint Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial
    Yun Yen
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010 3000, USA
    Cancer Chemother Pharmacol 50:353-9. 2002
    ..We are presently developing a phase II trial of this regimen for patients with platinum-resistant head and neck cancer...
  33. ncbi request reprint Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies
    Robert J Morgan
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Cancer Chemother Pharmacol 51:459-64. 2003
    ....
  34. ncbi request reprint Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine
    Harry Openshaw
    Department of Neurology, City of Hope National Medical Center, Duarte, California 91010, USA
    Clin Cancer Res 10:461-7. 2004
    ..To determine if there is a beneficial effect of amifostine in preventing or reducing the neuropathy induced by high-dose paclitaxel...
  35. ncbi request reprint Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy
    George Somlo
    Department of Medical Oncoilogy and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    J Clin Oncol 22:1839-48. 2004
    ..Tumor- and treatment-related factors were analyzed to generate a prognostic model...
  36. ncbi request reprint Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies
    Warren A Chow
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Cancer Chemother Pharmacol 54:241-8. 2004
    ..Since delivery of doxorubicin by 96-h continuous intravenous infusion also reduces cardiac injury, we studied delivering dexrazoxane and doxorubicin concomitantly by prolonged intravenous infusion...
  37. ncbi request reprint Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
    Robert J Morgan
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Cancer Chemother Pharmacol 54:283-9. 2004
    ....
  38. ncbi request reprint Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics
    Robert J Morgan
    Division of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California 91010, USA
    Clin Cancer Res 9:5896-901. 2003
    ..The purpose of this Phase I study was to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of i.p. docetaxel and to determine the peritoneal pharmacokinetics and pharmacological advantage of this agent...
  39. ncbi request reprint Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products
    Agnes Juhasz
    Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    J Clin Lab Anal 17:184-94. 2003
    ..By allowing the measurement of intratumoral target gene expression, these new methods may prove useful in predicting the clinical utility of gemcitabine- and platinum-containing chemotherapy programs in patients with solid tumors...
  40. ncbi request reprint A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer
    Yun Yen
    City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    Cancer Chemother Pharmacol 54:331-42. 2004
    ..A phase I trial was initiated to determine the safety profile and maximum tolerated doses of 3-AP and gemcitabine when used in combination in patients with advanced cancer...
  41. ncbi request reprint Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy
    Dean Lim
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA
    Invest New Drugs 23:235-9. 2005
    ..Plasma menadione concentrations peaked at 1.9-7.4 microM during the infusion in 3 patients receiving 1360 mg/m2. Further phase 1 and 2 combination trials using longer infusion durations have resulted from this trial...
  42. ncbi request reprint High dose chemotherapy and stem cell support in the treatment of germ cell cancer
    Kim Margolin
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA
    J Urol 169:1229-33. 2003
    ..The current status of high dose chemotherapy with autologous stem cell support in patients with germ cell cancer is reviewed...
  43. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  44. doi request reprint Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study
    Michael B Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 113:2139-45. 2008
    ..The authors tested the efficacy of a regimen including TMZ, thalidomide, and whole brain radiation therapy (WBRT) in patients with brain (CNS) metastases from melanoma...
  45. pmc Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center Vanderbilt, University Medical Center, Section of Hematology Oncology, 777 Preston Research Bldg, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:2292-8. 2008
    ..We evaluated 210M with one of three different IL-2 schedules to determine whether a basis exists for a phase III trial...
  46. ncbi request reprint Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA
    J Immunother 30:839-46. 2007
    ..Despite clinical efficacy, the study was closed prematurely owing to excess toxicity. Although all serious adverse events resolved, this degree of toxicity is unacceptable for an outpatient treatment regimen...
  47. ncbi request reprint Sunitinib efficacy against advanced renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:1883-7. 2007
    ..We assessed the efficacy of the oral multitargeted tyrosine kinase inhibitor sunitinib in patients with metastatic clear cell renal cell carcinoma...
  48. ncbi request reprint Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction
    Kim A Margolin
    Cancer 101:435-8. 2004
  49. ncbi request reprint Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer 106:2624-9. 2006
    ..To the authors' knowledge, no satisfactory therapy is available for patients with refractory germ cell neoplasms. The activity and safety of arsenic trioxide in refractory germ cell tumors was assessed...
  50. ncbi request reprint Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:247-56. 2007
    ..Serum tumor marker decline during chemotherapy was assessed prospectively as a predictor of treatment outcome...
  51. ncbi request reprint Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    J Clin Oncol 21:3133-40. 2003
    ..This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC)...
  52. doi request reprint State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA
    Cancer 113:1728-43. 2008
  53. ncbi request reprint The significance of solid tumor stem cells in melanoma: Part 2
    Kim A Margolin
    Curr Oncol Rep 10:430. 2008
  54. ncbi request reprint Kidney cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1072-81. 2006
  55. ncbi request reprint Testicular cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1038-58. 2006
  56. ncbi request reprint Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study
    Brian I Rini
    Department of Medicine, University of California San Francisco Cancer Center, San Francisco, California, USA
    Biol Blood Marrow Transplant 12:778-85. 2006
    ..A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach. Allogeneic SCT remains investigational in RCC...
  57. ncbi request reprint Sunitinib in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    JAMA 295:2516-24. 2006
    ..Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown activity in an initial study of cytokine-refractory metastatic RCC patients...
  58. ncbi request reprint The significance of solid tumor stem cells in melanoma: Part 1
    Kim A Margolin
    Curr Oncol Rep 10:429. 2008